Close
FINDING CURES TOGETHER<sup>SM</sup>

Second AACR International Conference
Translational Cancer Medicine
Cancer Discoveries for Clinical Application

​Program

Thursday, Sept. 27, 2018

Friday, Sept. 28, 2018

Saturday, Sept. 29, 2018


Thursday, Sept. 27, 2018

Welcome and Opening Keynote Lecture 
1:30-2:30 p.m.

Welcome and Introduction

Carlos L. Arteaga, UT Southwestern Simmons Cancer Center, Dallas, Texas

Keynote Lecture

Drew M. Pardoll, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland


Break

2:30-2:45 p.m.


Plenary Session 1: Immune Checkpoints: Mechanisms and Therapeutic Opportunities 

2:45-4:15 p.m.

Targeting regulatory T cells within tumors
Sergio A. Quezada, University College London Cancer Institute, London, England

An innate PD-1 axis potentially influences the response to immunotherapy
Cristina B. Bonorino, Federal University for Health Sciences of Porto Alegre, Porto Alegre, Brazil and University of California, San Diego, California

Immunotherapy for breast cancer: On the horizon
Leisha A. Emens, Johns Hopkins University School of Medicine, Baltimore, Maryland


Break
4:15-4:45 p.m.

 
Plenary Session 2: Precision Cancer Medicine 
4:45-6:15 p.m.

Title to be announced
Carlos H. Barrios, Carlos H. Barrios, Centro de Pesquisa Clínica Hospital São Lucas, PUCRS, Porto Alegre, Brazil

Precision medicine in patients with metastatic breast cancer
Fabrice André, Institut Gustave Roussy, Villejuif, France

Implementing precision strategies to address molecular heterogeneity for gastroesophageal adenocarcinoma
Daniel V. Catenacci, University of Chicago, Chicago, Illinois

Opening Reception
6:15 p.m.-8:30 p.m.

Top of page

Friday, Sept. 28, 2018 

Keynote Lecture 
8:45-9:30 a.m.
Session Chair: Carlos Gil Ferreira, Oncoclinicas Institute, São Paulo, Brazil

Introduction
Carlos Gil Ferreira

Galectins: Emerging regulatory checkpoints linking immunity and angiogenesis in cancer
Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina


Break
9:30-9:45 a.m.


Plenary Session 3: Epigenetics and Cancer Metabolism 
9:45-11 a.m.

Early metabolic reprogramming in glioma and breast cancer
Elizabeth Maher, UT Southwestern Simmons Cancer Center, Dallas, Texas

Epigenetic therapy regulates the tumor microenvironment to reduce immunosuppression and increase overall survival in a mouse model of ovarian cancer
Cynthia A. Zahnow, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

Epigenetic deregulation in normal and malignant hematopoiesis
María E. Figueroa, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida

                        
Break
11:15-11:30 a.m.               


Plenary Session 4: Translational Research in Leukemia and Lymphoma 
11:30 a.m.-12:30 p.m.

Mantle cell lymphoma as a model for translational science
Eduardo Sotomayor, George Washington Cancer Center, Washington, D.C.

Enhancing the function of CAR T cells by optimizing signaling
Marco L. Davila, Moffitt Cancer Center and Research Institute, Tampa, Florida

Clinical Trial Special Session 1
12:40 -1:10 p.m.

Poster Session A/Lunch
1:20-3:20 p.m.


Plenary Session 5: Use of Ex Vivo Models of Cancer to Advance Treatment  
3:30-5 p.m.

Organoid modeling of cancer
Calvin Kuo, Stanford University, Stanford, California

Use of PDXs, CDXs and syngeneic mouse models for personalized medicine
Maria Romina Girotti, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina

Title to be announced
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, Netherlands


Break
5-5:15 p.m.


Plenary Session 6: Virus-Induced Cancers: An Opportunity for Prevention  
5:15-6:45 p.m.

HPV-associated oral malignancies in the new era of targeted and immune therapies
J. Silvio Gutkind, UCSD Moores Cancer Center, La Jolla, California

KSHV-activation of PDGFRA as an oncogenesis driver and therapeutic target in Kaposi’s sarcoma
Enrique A. Mesri, University of Miami Miller School of Medicine, Miami, Florida

Title to be announced
Luisa L. Villa, Fundação Faculdade de Medicina de São Paulo, São Paulo, Brazil


Evening Off/Dinner on Own
6:45 p.m.
 

Top of page

Saturday, Sept. 29, 2018 

Keynote Lecture  
8:45-9:30 a.m.
Session Chair: Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina

Introduction
Gabriel A. Rabinovich

Novel applications of cancer genomics
Luis A. Diaz, Jr., Memorial Sloan Kettering Cancer Center, New York, New York


Break
9:30-9:45 a.m.


Plenary Session 7: The Microbiome and Cancer  
9:45-10:45 a.m.

Microbiota reconstitution restores intestinal integrity after cisplatin therapy
Jose R. Conejo-Garcia, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Title to be announced
Giorgio Trinchieri, National Cancer Institute, Bethesda, Maryland


Break
10:45-11 a.m.

Plenary Session 8: Nuclear Steroid Receptors: Translational Implications  
11 a.m.-12:30 p.m.

Title to be announced
Myles Brown, Dana-Farber Cancer Institute, Boston, Massachusetts

The ratio of progesterone receptor isoforms in breast cancer matters
Claudia Lanari, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina

Targeting the bone compartment in metastatic prostate cancer
Nora M. Navone, The University of Texas MD Anderson Cancer Center, Houston, Texas


Clinial Trial Special Session 2
12:40-1:10 p.m.


Poster Session B/Lunch
1:20-3:20 p.m.


Plenary Session 9: Targeting Tumor Heterogeneity: Obstacles and Opportunities 
3:30-5 p.m.

Title to be announced
Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York

Disseminated cancer cells dormancy: How it might impact metastasis prevention
Julio A. Aguirre-Ghiso, Icahn School of Medicine at Mount Sinai, New York, New York

Title to be announced
Dirce Maria Carraro, A.C. Camargo Cancer Center, São Paulo, Brazil


Closing Remarks
5:15-5:30 p.m.

Carlos L. Arteaga, UT Southwestern Simmons Cancer Center, Dallas, Texas

Carlos Gil Ferreira, Oncoclinicas Institute, São Paulo, Brazil

Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina

Top of page